The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Novo Nordisk A/S (NYSE:NVO) Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 Novo Nordisk Earnings Conference Call.

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug franchises. Learn more on NVO stock here.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

Novo Nordisk(NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

Although Novo Nordisk continues to post double-digit increases thanks largely to Wegovy and Ozempic, it has been in the investor doghouse so far this month.

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings ...

Stock futures were rising again on the eve of another tariff deadline as investors juggled strong earnings with more signs of U.S. economic weakness. Shares closed in the red Tuesday after the ISM ...

Novo Nordisk said sales of its blockbuster Wegovy weight-loss drug soared last quarter. (Hollie Adams/Reuters) ↘️ Novo Nordisk (NVO): The pharmaceutical company's quarterly sales of its ...

Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales.